Immunomedics (IMMU) stock price, revenue, and financials

Immunomedics market cap is $20.3 b, and annual revenue was $295 k in FY 2019

$20.3 B

IMMU Mkt cap, 26-Oct-2020

$20.1 M

Immunomedics Revenue Q2, 2020
Immunomedics Gross profit (Q2, 2020)18.4 M
Immunomedics Gross profit margin (Q2, 2020), %91.7%
Immunomedics Net income (Q2, 2020)-66.5 M
Immunomedics EBIT (Q2, 2020)-53 M
Immunomedics Cash, 30-Jun-2020971.2 M
Immunomedics EV19.3 B
Get notified regarding key financial metrics and revenue changes at ImmunomedicsLearn more
Banner background

Immunomedics Revenue

Immunomedics revenue was $295 k in FY, 2019 which is a 86.3% year over year decrease from the previous period.

Embed Graph

Immunomedics Revenue Breakdown

Embed Graph

Immunomedics revenue breakdown by business segment: 15.3% from License fee and other revenues, 15.1% from Research and development and 69.6% from Product sales

Immunomedics Income Statement

Annual

USDFY, 2017FY, 2018FY, 2019

Revenue

3.1m2.2m295.0k

Revenue growth, %

(4%)(30%)(86%)

Cost of goods sold

482.7k613.6k

Gross profit

2.6m1.5m295.0k

Gross profit Margin, %

84%72%100%

Sales and marketing expense

873.2k6.8m26.5m

R&D expense

51.8m99.3m254.9m

General and administrative expense

29.1m36.5m43.8m

Operating expense total

81.8m142.6m325.1m

EBIT

(79.1m)(141.0m)(324.8m)

EBIT margin, %

(2560%)(6542%)(110115%)

Interest expense

5.5m23.3m40.3m

Pre tax profit

(153.2m)273.7m(357.3m)

Income tax expense

20.9k155.8k

Net Income

(153.2m)273.9m(357.3m)

EPS

(1.5)(1.8)(0.8)

Immunomedics Balance Sheet

Annual

USDFY, 2017FY, 2018FY, 2019

Cash

43.4m612.1m608.6m

Accounts Receivable

488.7k45.8k295.0k

Prepaid Expenses

891.3k3.8m21.8m

Inventories

580.0k

Current Assets

157.3m648.4m638.7m

PP&E

5.2m15.7m32.8m

Total Assets

162.6m664.2m671.7m

Accounts Payable

31.4m31.7m60.9m

Short-term debt

90.7m9.0m7.4m

Current Liabilities

122.2m43.7m71.8m

Long-term debt

98.1m19.8m10.0m

Total Debt

188.8m28.7m17.4m

Total Liabilities

222.0m264.5m404.5m

Common Stock

1.1m1.9m2.1m

Additional Paid-in Capital

462.7m1.2b1.6b

Retained Earnings

(521.7m)(795.5m)(1.3b)

Total Equity

(59.5m)399.7m267.2m

Debt to Equity Ratio

-3.2 x0.1 x0.1 x

Debt to Assets Ratio

1.2 x0 x0 x

Financial Leverage

-2.7 x1.7 x2.5 x

Immunomedics Cash Flow

Annual

USDFY, 2017FY, 2018FY, 2019

Net Income

(153.3m)(273.9m)(357.3m)

Depreciation and Amortization

923.3k1.3m3.8m

Accounts Receivable

102.6k452.3k(295.0k)

Inventories

(196.0k)580.0k

Accounts Payable

15.8m(1.5m)30.0m

Cash From Operating Activities

(62.3m)(134.0m)(222.4m)

Purchases of PP&E

(1.8m)(10.0m)(6.8m)

Cash From Investing Activities

(76.3m)74.8m(6.8m)

Cash From Financing Activities

168.8m627.9m347.2m

Net Change in Cash

30.2m568.7m117.9m

Interest Paid

4.8m2.9m338.0k

Income Taxes Paid

23.6k

Immunomedics Ratios

USDFY, 2017

Revenue/Employee

23.6k

Debt/Equity

-3.2 x

Debt/Assets

1.2 x

Financial Leverage

-2.7 x

Immunomedics Operating Metrics

Immunomedics's Properties was reported to be 2 in FY, 2019.
FY, 2017FY, 2018FY, 2019Sep, 2020

Approval Phase Products

11

Office and Other Space, sq. ft.

130.7 k136.5 k130.7 k

Patent Applications (US)

275

Patents (US)

390

Phase I Trials Products

12

Phase II Trials Products

444

Phase III Trials Products

124

Pre-Clinical Phase Products

11

Properties

232

Immunomedics Human Capital

Job Roles

FY, 2019FY, 2018FY, 2017
Production49.7%45.9%58.1%
Management and Administration30.9%24.9%18.4%
Product Research and Development 19.4%29.2%23.5%

Immunomedics Employee Rating

2.941 votes
Culture & Values
3.2
Work/Life Balance
2.7
Senior Management
2.7
Salary & Benefits
3.8
Career Opportunities
2.9
Source